Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, has announced its participation in two major healthcare conferences in March 2025. The company will engage in analyst-led fireside chats at:
- The Raymond James 46th Annual Institutional Investors Conference on March 5th at 10:25AM ET
- The Barclays 27th Annual Global Healthcare Conference on March 12th at 8:00AM ET
Both events will be accessible via live audio on the company's website investor.pacira.com under the 'Events' section. Webcasts will remain available for replay for two weeks following each event.
Pacira BioSciences (PCRX) has announced it will release its fourth quarter and full-year 2024 financial results after U.S. markets close on Thursday, February 27, 2025. The company will host a conference call and webcast at 4:30 p.m. ET on the same day.
Interested participants can pre-register for the Q&A session via telephone, and all registrants will receive dial-in information and a PIN for call access. The conference call will also be available as a webcast through the 'Events' page on Pacira's investor website. A replay of the webcast will be accessible on the company's website for approximately two weeks following the call.
Pacira BioSciences (PCRX) announced inducement grants to 15 new employees on February 4, 2025, under its Amended and Restated 2014 Inducement Plan. The grants include significant awards to two key executive appointments: Brendan Teehan as Chief Commercial Officer and Krys Corbett as Chief Business Officer.
Teehan received options to purchase 99,500 shares at $26.59 per share and 54,000 restricted stock units (RSUs). Corbett received options for 88,400 shares at $26.59 and 46,000 RSUs. Additionally, four employees received options to purchase 20,600 shares, and 13 employees received 45,400 RSUs.
The stock options have a 10-year term with four-year vesting schedules. RSUs vest in four equal annual installments starting February 1, 2026. All awards are subject to continued employment with Pacira.
Pacira BioSciences (PCRX) announced significant changes to its Board of Directors. Laura Brege has been appointed as Chair of the Board, while former Chair Paul J. Hastings and Andreas Wicki have retired. The Board now consists of nine directors, with eight being independent and five joining since October 2023.
Brege brings over a decade of experience with Pacira and 30 years of executive management expertise in the pharmaceutical and biotechnology industries. She has held executive positions at BridgeBio Pharma, Onyx Pharmaceuticals, and COR Therapeutics.
These changes are part of Pacira's ongoing Board transformation, which began 15 months ago with the appointment of four new independent directors. Additionally, Alethia Young has been appointed as the new Chair of the Audit Committee, succeeding Brege in this role.
Pacira BioSciences (NASDAQ: PCRX) has announced two key appointments to its executive leadership team as part of its '5x30' strategy to become an innovative biopharmaceutical organization. Brendan Teehan has been appointed as Chief Commercial Officer, bringing 30 years of experience in building commercial teams across multiple therapeutic categories. Previously, he served as Chief Operating Officer at Acadia Pharmaceuticals.
Krys Corbett joins as Chief Business Officer, contributing over 25 years of experience in business development and strategic transactions. She previously led portfolio and product strategy at Lyell Immunopharma and served as Head of Business Development at Oric Pharmaceuticals.
These appointments are intended to enhance the company's execution of its growth strategy, combining Teehan's expertise in maximizing pharmaceutical brands with Corbett's portfolio management and partnering experience.
Pacira BioSciences (PCRX) announced its five-year strategic plan '5x30' alongside preliminary unaudited 2024 revenue of $701.0 million, up from $675.0 million in 2023. The 5x30 plan aims to achieve five key objectives by 2030, including treating over three million patients annually, achieving double-digit revenue growth, improving gross margin by five percentage points, expanding clinical pipeline with five novel programs, and establishing five partnerships.
Key 2024 revenue highlights include EXPAREL net product sales of $549.0 million (up from $538.1 million in 2023), ZILRETTA sales of $118.1 million (up from $111.1 million), and iovera° sales of $22.8 million (up from $19.7 million). Fourth quarter EXPAREL sales reached $147.7 million, with growth driven by volume increases and pricing, partially offset by vial mix shifts and GPO partnership discounts.
Pacira BioSciences (Nasdaq: PCRX) has received FDA 510(k) clearance for a new Smart Tip designed for the iovera° system to manage chronic low back pain via long-lasting medial branch nerve block. The iovera° system uses cryoneurolysis, applying focused cold therapy to nerves to interrupt pain signals temporarily. The new 25-gauge, 180-mm Smart Tip treats deeper nerves, including the medial branch nerve, and is designed to relieve chronic low back pain associated with facet-mediated pain.
Chronic low back pain is a significant health issue in the U.S., leading to disability and opioid prescriptions. The iovera° system provides an alternative to radiofrequency ablation (RFA), which has limitations like delayed pain relief and potential tissue damage. A single-center randomized pilot study showed that patients treated with iovera° reported pain scores more than 2 points lower at 180 and 360 days compared to RFA-treated patients. Additionally, iovera° patients exhibited significant functional improvements and greater satisfaction with pain management.
The FDA clearance of this new Smart Tip is a step forward in offering drug-free, effective pain relief for millions of Americans with chronic back pain.
Pacira BioSciences (NASDAQ: PCRX) has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025, at 10:30 AM PT (1:30 PM EST).
Interested parties can access the live audio presentation through the 'Events' page on the company's investor website at investor.pacira.com. The company will make a replay of the webcast available for a two-week period following the event.
VectorY Therapeutics announces Jim Scibetta as new CEO, while former CEO Sander van Deventer transitions to President of R&D. The company's lead program, VTx-002, a vectorized antibody targeting TDP-43 for ALS treatment, advances to IND-enabling studies following positive FDA feedback. The company recently completed a $138 million Series A funding round co-led by EQT Life Sciences and Forbion, and expanded its presence with a new office in Boston.
Scibetta brings over 20 years of executive leadership experience, including roles as CEO of Maverick Therapeutics and President of Pacira BioSciences. VTx-002 aims to delay ALS disease progression by targeting TDP-43 pathology and is expected to enter clinical trials by the end of 2025.
DOMA Perpetual Capital Management, owning 4.14% of Pacira BioSciences (NASDAQ: PCRX), announced plans to nominate four independent director candidates for Pacira's 2025 annual stockholder meeting. DOMA has hired Olshan Frome Wolosky LLP as legal counsel for company dealings.
Expressing strong confidence in Pacira's intellectual property value, DOMA believes the company's stock is significantly undervalued. They are urging Pacira to initiate an immediate stock tender offer for 10 million shares using available cash reserves, followed by executing their previously approved $150 million buyback program using the company's healthy and growing free cash flow.